Drug therapy advances have slashed the rate of hypos: study
Danish data highlight the relatively greater risk with use of human insulins and sulfonylureas, researchers say
Development of insulin analogues and newer drug classes for diabetes likely lie behind a fall of more than 60% in hospital admissions for hypoglycaemia, Danish researchers say.
Among patients with type 2 diabetes, the move away from sulfonylureas to metformin, DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors has increased patient safety, their study suggests.
